Kura Oncology Inc (NASDAQ: KURA) stock jumped 5.17% on Friday to $9.56 against a previous-day closing price of $9.09. With 0.5 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.63 whereas the lowest price it dropped to was $9.07. The 52-week range on KURA shows that it touched its highest point at $16.14 and its lowest point at $7.41 during that stretch. It currently has a 1-year price target of $28.05. Beta for the stock currently stands at 0.64.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KURA was up-trending over the past week, with a rise of 12.21%, but this was up by 15.74% over a month. Three-month performance dropped to -12.45% while six-month performance fell -25.60%. The stock lost -37.11% in the past year, while it has lost -22.97% so far this year. A look at the trailing 12-month EPS for KURA yields -2.02 with Next year EPS estimates of -2.26. For the next quarter, that number is -0.55. This implies an EPS growth rate of -2.50% for this year and -8.47% for next year. EPS is expected to grow by 19.93% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -5.93%.
Float and Shares Shorts:
At present, 68.31 million KURA shares are outstanding with a float of 65.81 million shares on hand for trading. On Oct 30, 2023, short shares totaled 10.1 million, which was 13.60% higher than short shares on Sep 28, 2023. In addition to Dr. Troy Edward Wilson J.D., Ph.D. as the firm’s Chairman, CEO & President, Ms. Kathleen Ford serves as its Chief Operating Officer.
Through their ownership of 100.91% of KURA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 65.39% of KURA, in contrast to 26.19% held by mutual funds. Shares owned by individuals account for 10.15%. As the largest shareholder in KURA with 9.88% of the stake, Suvretta Capital Management LLC holds 7,335,845 shares worth 7,335,845. A second-largest stockholder of KURA, BVF Partners LP, holds 6,730,983 shares, controlling over 9.07% of the firm’s shares. EcoR1 Capital, LLC is the third largest shareholder in KURA, holding 5,806,871 shares or 7.82% stake. With a 2.97% stake in KURA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,207,564 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 2.71% of KURA stock, is the second-largest Mutual Fund holder. It holds 2,012,563 shares valued at 17.01 million. iShares Russell 2000 ETF holds 2.22% of the stake in KURA, owning 1,650,733 shares worth 13.95 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KURA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With KURA analysts setting a high price target of $37.00 and a low target of $10.50, the average target price over the next 12 months is $28.05. Based on these targets, KURA could surge 287.03% to reach the target high and rise by 9.83% to reach the target low. Reaching the average price target will result in a growth of 193.41% from current levels.
Summary of Insider Activity:
Insiders traded KURA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 415,269 while 904,678 shares were sold.